Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 4 Correlation of PARK-2 promoter methylation with clinical parameters among breast cancer patients

From: Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients

S No. Variables Total Parkin Promoter P valuea OR (95%CI)
Unmethylated Methylated
1 Age (Years) < 50 30 14 (47) 16 (53) 1.000 1.0259 (0.4617–2.2791)
≥50 126 58 (46) 68 (54)
2 Weight (Kg) < 60 75 36 (48) 39 (52) 0.748 1.1538 (0.6143–2.1672)
≥60 81 36 (44) 45 (56)
3 Tumour size (cm) < 4’ 73 37 (51) 36 (49) 0.335 1.4095 (0.7487–2.6537)
≥4 83 35 (42) 48 (58)
4 Clinical Stage I + II 88 36 (41) 52 (59) 0.148 0.6154 (0.3251–1.1650)
III + IV 68 36 (53) 32 (47)
5 Histological gradeb WD 54 33 (61) 21 (39) 0.007* 2.5385 (1.2894–4.9974)
MD + PD 102 39 (38) 63 (62)
6 Lymph Node Negative 81 42 (52) 39 (48) 0.151 1.6154 (0.8559–3.0487)
Positive 75 30 (46) 45 (54)
7 Menopause Pre 38 23 (61) 15 (39) 0.061 2.1592 (1.0235–4.5549)
Post 118 49 (42) 69 (58)
8 ERc Negative 81 41 (51) 40 (49) 0.264 1.4548 (0.7723–2.7404)
Positive 75 31 (41) 44 (59)
9 PRd Negative 103 49 (48) 54 (52) 0.735 1.1836 (0.6076–2.3056)
Positive 53 23 (43) 30 (57)
10 Her-2e Negative 111 61 (55) 50 (45) 0.001* 3.7709 (1.7351–8.1925)
Positive 45 11 (24) 34 (76)
11 TNBCf No 106 49 (46) 57 (54) 1.000 1.0092 (0.5140–1.9812)
Yes 50 23 (46) 27 (54)
  1. a Fisher’s exact test, *Significant Correlation (P < 0.05)
  2. b WD Well differentiated, MD Moderately differentiated, PD Poorly differentiated
  3. c Estrogen receptor
  4. d Progesterone receptor
  5. e human epidermal growth factor receptor 2
  6. f Triple negative breast cancer